Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients—A Single-Center Case-Control Study

Petenyi, Flora Greta; Garay, Tamás; Mühl, Dorottya; Izso, Blanka; Karászi, Ádám; Borbenyi, Erika; Herold, Magdolna; Herold, Zoltán; Szász, Attila Marcell; Dank, Magdolna

doi:10.3390/diseases9040081

Cited by 7 publications

(4 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Clinical Validationmentioning

confidence: 99%

“… Comparison of the survival studies of advanced pancreas carcinomas ① [ 75 ] ( n = 106), ② [ 99 ] ( n = 25), ③ [ 120 ] ( n = 99), ④ [ 76 ] ( n = 78), ⑤ [ 120 ] ( n = 34), ⑥ SEER (NCI, USA) data from [ 99 ]. …”

Section: Figurementioning

confidence: 99%

“…Retrospective observational study with mEHT-treated and untreated arms for advanced pancreatic cancer showed that mEHT was successfully applicable for various pancreatic tumors [75], and also for the specially nonresectable tumors compared to PSM [76], as well as relative long overall survival; Table 5. A randomized double-arm Phase II study (n = 49 + 48) showed significant improvement in survival and quality of life for patients with Stage III-IV NSCLC treated with mEHT in combination with high-dose vitamin C infusion and providing the best supportive care (BSC) in both arms [79].…”

Section: Survival Timementioning

confidence: 99%

“…A comparison of the Kaplan-Meier survival curves shows a definite similarity in the survival probabilities, Figure 7, without such unified curves as we observed in GBM. [75] (n = 106), 2 [99] (n = 25), 3 [120] (n = 99), 4 [76] (n = 78), 5 [120] (n = 34), 6 SEER (NCI, USA) data from [99].…”

Section: Comparison Of Survival Curvesmentioning

confidence: 99%

See 3 more Smart Citations

The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)

Lee,

Lorant,

Grand

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

The mEHT method uses tissues’ thermal and bioelectromagnetic heterogeneity for the selective mechanisms. The success of the therapy for advanced, relapsed, and metastatic aggressive tumors can only be demonstrated by measuring survival time and quality of life (QoL). The complication is that mEHT-treated patients cannot be curatively treated any longer with “gold standards”, where the permanent progression of the disease, the refractory, relapsing situation, the organ failure, the worsening of blood counts, etc., block them. Collecting a cohort of these patients is frequently impossible. Only an intent-to-treat (ITT) patient group was available. Due to the above limitations, many studies have single-arm data collection. The Phase III trial of advanced cervix tumors subgrouping of HIV-negative and -positive patients showed the stable efficacy of mEHT in all patients’ subgroups. The single-arm represents lower-level evidence, which can be improved by comparing the survival data of various studies from different institutes. The Kaplan–Meier probability comparison had no significant differences, so pooled data were compared to other methods. Following this approach, we demonstrate the feasibility and superiority of mEHT in the cases of glioblastoma multiform, pancreas carcinomas, lung tumors, and colorectal tumors.

show abstract

Section: Clinical Validationmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Section: Survival Timementioning

confidence: 99%

Section: Comparison Of Survival Curvesmentioning

confidence: 99%

See 2 more Smart Citations

The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)

Lee,

Lorant,

Grand

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

Targeting the heat shock response induced by modulated electro-hyperthermia (mEHT) in cancer

Viana,

Hamar

2024

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients

Kleef,

Dank,

Herold

et al. 2023

Sci Rep

View full text Add to dashboard Cite

In the last decade, the use of immunomodulating treatments (IMT) at integrative oncology providers (IOP) increased. IMTs are used to modulate the tumor microenvironment, which might lead to increased response-to-treatment, and the indication of immune checkpoint inhibitors might also be widened. The efficacy and safety of IMTs in advanced/metastatic gastrointestinal cancers were compared with conventional chemo(radio)therapy (CT). 21 colorectal– (CRC), 14 pancreatic– (PC), 5 cholangiocellular– (CCC), 5 gastric– (GC) and 4 esophageal cancer (EC) patients received IMT. IMT and CT were compared in CRC and PC. CT was administered at an academic oncology center. After the initiation of IMT, a median survival of ~ 20 (CRC, PC and EC) and ~ 10 months (CCC and GC) was observed. Of the IMTs, locoregional modulated electro-hyperthermia had the most positive effect on overall survival (HR: 0.3055; P = 0.0260), while fever-inducing interleukin-2, and low-dose ipilimumab showed a positive tendency. IMT was superior to CT in PC (HR: 0.1974; P = 0.0013), while modest effect was detected in CRC (HR: 0.7797; P = 0.4710). When the whole study population was analyzed, IMTs showed minimal effect on patient survival, still CT had the greatest effect if introduced as early as possible (HR: 0.0624; P < 0.0001). The integrative IMTs in the presented form have mild impact on gastrointestinal cancer patients’ survival, however, we observed its benefit in PC, which warrants further investigations.

show abstract

Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients—A Single-Center Case-Control Study

Cited by 7 publications

References 54 publications

The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)

The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)

Targeting the heat shock response induced by modulated electro-hyperthermia (mEHT) in cancer

Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients

Contact Info

Product

Resources

About